0001209191-23-050548.txt : 20230926
0001209191-23-050548.hdr.sgml : 20230926
20230926155848
ACCESSION NUMBER: 0001209191-23-050548
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230925
FILED AS OF DATE: 20230926
DATE AS OF CHANGE: 20230926
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MIDDLETON FRED A
CENTRAL INDEX KEY: 0001267959
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35867
FILM NUMBER: 231280444
MAIL ADDRESS:
STREET 1: 400 SOUTH EL CAMINO REAL STE 1200
CITY: SAN MATEO
STATE: CA
ZIP: 94402-1708
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CHIMERIX INC
CENTRAL INDEX KEY: 0001117480
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 330903395
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2505 MERIDIAN PARKWAY, SUITE 100
CITY: DURHAM
STATE: NC
ZIP: 27713
BUSINESS PHONE: 919.806.1074
MAIL ADDRESS:
STREET 1: 2505 MERIDIAN PARKWAY, SUITE 100
CITY: DURHAM
STATE: NC
ZIP: 27713
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-09-25
0
0001117480
CHIMERIX INC
CMRX
0001267959
MIDDLETON FRED A
C/O CHIMERIX, INC.
2505 MERIDIAN PARKWAY, SUITE 100
DURHAM
NC
27713
1
0
0
0
0
Common Stock
2023-09-25
4
P
0
20000
0.9818
A
80000
I
Fred A. Middleton Separate Property Trust
Common Stock
207523
D
Common Stock
2776093
I
See footnote
Common Stock
531861
I
See footnote
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.9746 to $0.985, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information will be provided regarding the number of shares purchased or sold at each separate price.
The securities are held as follows: 829,046 shares of common stock held by Sanderling Venture Partners V, L.P., 233,134 shares of common stock held by Sanderling V Biomedical, L.P., 155,143 shares of common stock held by Sanderling V Limited Partnership, 138,046 shares of common stock held by Sanderling V Beteiligungs GmbH & Co. KG, 199,853 shares of common stock held by Sanderling V Biomedical Co-Investment Fund, L.P., 329,682 shares of common stock held by Sanderling Venture Partners V Co-Investment Fund, L.P. and 891,189 shares of common stock held by Sanderling V Strategic Exit Fund, L.P. (collectively, the Sanderling V Shares).
The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling V Shares and the Sanderling VI Shares (as defined herein). The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
The securities are held as follows: 498,046 shares of common stock held by Sanderling Venture Partners VI Co-Investment Fund, L.P., 15,431 shares of common stock held by Sanderling VI Beteiligungs GmbH & Co. KG and 18,384 shares of common stock held by Sanderling VI Limited Partnership (collectively, the Sanderling VI Shares).
/s/ Michael Alrutz, Attorney-In-Fact
2023-09-26